Maintenance Therapy in Multiple Myeloma
Rene Gauducheau Cancer Center, Bd Jacques Monod, CEDEX, 44805 Nantes/St. Herblain, France
Hematol. Rev. 2009, 1(2), e12; https://doi.org/10.4081/hr.2009.e12 (registering DOI)
Submission received: 23 July 2009
/
Revised: 30 July 2009
/
Accepted: 1 August 2009
/
Published: 5 August 2009
Excerpt
Note: In lieu of an abstract, this is an excerpt from the first page.
The treatment of multiple myeloma (MM) has changed dramatically in the past twenty years with the introduction of high-dose therapy plus autologous stem-cell transplantation (ASCT) in younger patients and, more recently, of three novel agents (thalidomide, bortezomib, and lenalidomide) [...]
Share and Cite
MDPI and ACS Style
Harousseau, J.-L. Maintenance Therapy in Multiple Myeloma. Hematol. Rev. 2009, 1, e12. https://doi.org/10.4081/hr.2009.e12
AMA Style
Harousseau J-L. Maintenance Therapy in Multiple Myeloma. Hematology Reviews. 2009; 1(2):e12. https://doi.org/10.4081/hr.2009.e12
Chicago/Turabian StyleHarousseau, Jean-Luc. 2009. "Maintenance Therapy in Multiple Myeloma" Hematology Reviews 1, no. 2: e12. https://doi.org/10.4081/hr.2009.e12
